Indometacin Sopharma (Indometacin)

Indometacin blocks the activity of cyclooxygenase enzymes (COX‑1 and COX‑2), which are essential for producing prostaglandins—molecules that promote inflammation, pain, and fever. By reducing prostaglandin synthesis, indometacin diminishes the inflammatory response and alleviates associated discomfort.

The specific dose and frequency of Indometacin Sopharma are determined by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety of indometacin during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Indometacin Sopharma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indometacin is a potent NSAID with strong anti‑inflammatory activity, often considered more effective for certain acute gout attacks compared with ibuprofen or naproxen. However, its gastrointestinal and renal risk profile may be higher, so clinicians weigh efficacy against safety when selecting an NSAID for each patient.

Indometacin Sopharma should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme temperatures to maintain stability and potency.

The product is a cutaneous preparation intended for external use. Apply a thin layer to clean, dry skin over the affected area, gently rub it in, and wash hands after application. Follow the prescriber’s instructions regarding frequency and duration of use.

Serious risks include gastrointestinal ulceration or bleeding, severe renal impairment, hepatotoxicity, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored for signs of these events and seek immediate medical attention if they occur.

Individuals with a known hypersensitivity to indometacin or other NSAIDs, active peptic ulcer disease, severe renal or hepatic impairment, and those on anticoagulant therapy without close monitoring should avoid using this product. A healthcare professional should evaluate suitability before initiating therapy.